Recordati

Focus: Recordati is a mid-cap specialty pharmaceutical company headquartered in France with 1,001–5,000 employees, focused on small-molecule manufacturing across oncology, rare diseases, endocrinology, cardiovascular, and hematology. The company is public and generates 67% of revenue from its flagship product ISTURISA.

Oncology Endocrinology Rare Diseases Cardiovascular

Profile data last refreshed 21h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Employees

1001-5000

Open Jobs

About Recordati

AI assessmentNot Hiring

No open roles listed right now. Follow Recordati to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

5/9 — Partial

Company HealthSolid

Pipeline

Late-stage

5 Phase 3+

LOE Risk

3 imminent

CARBAGLU

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

ISTURISA

Cushing's syndrome (cortisol-lowering)

$35M Part D

Peak9.2yr

Blockbuster-scale rare-disease drug; 11β-hydroxylase inhibitor generating 67% of company revenue with 9-year patent runway.

Help build intelligence for Recordati

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Peak revenue product (ISTURISA) with LOE protection until 2035 provides stable funding for specialty-focused R&D in rare and endocrine disorders.
Diverse portfolio across oncology, hematology, and rare diseases offers career mobility across multiple therapeutic areas with defined patient populations.
Pipeline breadth including Phase 2/3 programs (Siltuximab for ARDS, Silodosin for BPH, Pasireotide extensions) suggests ongoing clinical development velocity.

Watch Out For

Heavy revenue concentration (67% ISTURISA) creates vulnerability if commercial performance slips; only $10M in additional products face LOE by 2028.
Recent private-equity takeover interest (CVC Capital Partners bid announced May 2026) signals potential delisting, restructuring, and culture disruption ahead.
Limited Phase 3 pipeline (0 active Phase 3 programs) and modest publication output (5 papers) indicate slower innovation velocity vs. larger specialty peers.

Generated by Claude from Recordati's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CARBAGLU

Hyperammonemia (rare metabolic disorder)

$9M Part D

LOE Approaching1.5yr

Second-largest product; CPS1 activator for urea-cycle disorders facing patent expiration in ~2 years.

CYSTADANE

Homocystinuria (rare metabolic disorder)

$3M Part D

LOE Approaching

Methylating agent for cysteine metabolism; mature rare-disease product with modest revenue.

CYSTADROPS

Cystinosis (rare lysosomal storage disease)

$2M Part D

Peak

Ophthalmologic cystine-depleting agent; niche rare-disease indication with long-term market position.

SIGNIFOR

Cushing's disease, acromegaly

$1M Part D

LOE Approaching0.4yr

Somatostatin receptor agonist facing patent cliff in 7 months; modest revenue but active pipeline expansion into prolactin tumors.

ENJAYMO

Cold agglutinin disease (rare autoimmune hemolytic anemia)

$1M Part D

Peak

First-in-class complement inhibitor (BLA) for rare hematologic disease; growth potential as awareness expands.

CHEMET

Lead poisoning in pediatric patients

$153K Part D

LOE Approaching

Lead-chelating agent for pediatric toxicology; minimal revenue, regulatory niche product.

PEGANONE

Seizure disorders

LOE Approaching

Legacy antiepileptic; no reported Part D spending, likely post-patent generic or discontinued.

DACTINOMYCIN

Nonseminomatous testicular cancer, other solid tumors

Post-LOE

Nucleic-acid synthesis inhibitor (ANDA); post-LOE generic chemotherapy with minimal branded revenue.

DACTINOMYCIN

Nonseminomatous testicular cancer, multi-phase combination regimens

Post-LOE

Duplicate ANDA entry for dactinomycin; post-LOE generic status indicates commodity oncology product.

Pipeline & Clinical Trials

Lactobacillus salivarius V4II-90

Gestational Mother

N/A

Clinical Trials (1)

NCT03669094Effect of a New Probiotic Strain in the Reduction of Group B Streptococcus Colonization in Pregnant Women

N/A

Lactobacillus salivarius PS7 during 6 months

Acute Otitis Media

N/A

Clinical Trials (1)

NCT03614117Effect of a New Probiotic Strain on Recurrent Acute Otitis Media in Children (PROMAR)

N/A

Bowel preparation

Bowel Preparation for Colonoscopy

N/A

Clinical Trials (1)

NCT02839824Evaluation of the Quality of Bowel Cleansing in a Real Clinical Practice Setting

N/A

Various labs and imaging tests

Mild Autonomous Cortisol Secretion (MACS)

N/A

Clinical Trials (1)

NCT06344143Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma

N/A

Colombia National Porphyria Registry

Rare Diseases

N/A

Clinical Trials (1)

NCT05496933Colombia National Porphyria Registry

N/A

intradermal pholcodine allergy test in cases

Neuromuscular Blocking Agents Anaphylaxis

N/A

Colonization with Group B Streptococcus During Pregnancy

Gestational Mother

N/A

Clinical Trials (1)

NCT03671486Colonization with Group B Streptococcus During Pregnancy

N/A

Cross-sectional, Non-randomized Observational Study to Assess the Frequency of Reduced Sodium Intake

Dietary Deficiency

N/A

Clinical Trials (1)

NCT06121583Cross-sectional, Non-randomized Observational Study to Assess the Frequency of Reduced Sodium Intake in the Primary Care Setting - LAXAP

N/A

Data-collection

Neuroblastoma

N/A

Clinical Trials (1)

NCT04253015A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta

N/A

Sutimlimab

Cold Agglutinin Disease (CAD)

N/A

Clinical Trials (1)

NCT05791708Cold Agglutinin Disease Real World Evidence Registry

N/A

Research questions

Idiopathic Multicentric Castleman's Disease

N/A

Clinical Trials (1)

NCT05995834Producing a Novel Symptom Burden Scale for People Living With Idiopathic Multicentric Castleman Disease (ISBUS)

N/A

Pasireotide

Cushings Disease

N/A

Clinical Trials (1)

NCT02310269Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease

N/A

Leuprolide Acetate

Prostate Cancer

N/A

Clinical Trials (1)

NCT03990194Real-life Study of Patients After 3-months of Leuprorelin 5mg Implant in Prostate Cancer

N/A

The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients

Mycosis Fungoides

N/A

Clinical Trials (1)

NCT06421571The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients

N/A

Osilodrostat

Endogenous Cushing's Syndrome

N/A

Clinical Trials (1)

NCT05382156Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

N/A

Carglumic Acid

Hyperammonemia

N/A

Clinical Trials (1)

NCT05040178An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics

N/A

Interest of a Systematic Assessment of the Treatment of LUTS in the Management of BPH

Benign Prostatic Hyperplasia

N/A

Clinical Trials (1)

NCT03179670Interest of a Systematic Assessment of the Treatment of LUTS in the Management of BPH

N/A

Chlormethine

Mycosis Fungoides

N/A

Osilodrostat

Endogenous Cushing Syndrome

N/A

Clinical Trials (1)

NCT06430528A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement

N/A

Osilodrostat

Cushing's Syndrome

N/A

Clinical Trials (1)

NCT05633953Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome

N/A

Long-term Assessment of Chlormethine Gel in Mycosis Fungoides

Cutaneous T-Cell Lymphoma/Mycosis Fungoides

N/A

Clinical Trials (1)

NCT07046663Long-term Assessment of Chlormethine Gel in Mycosis Fungoides

N/A

Methadone

Cancer Pain

N/A

Clinical Trials (1)

NCT05265442Real-life Observational Study of Cancer Pain Management With Methadone

N/A

Carglumic Acid

Methylmalonic Acidemia

N/A

Clinical Trials (1)

NCT04176523Understanding the Long-Term Management of Organic Acidemia Patients With CARBAGLU®: A Mixed Methods Approach

N/A

Siltuximab

Non-Hodgkin Lymphoma

PHASE_1

Pasireotide cartridge with reusable ServoPen

Pharmacokinetics

PHASE_1

Clinical Trials (1)

NCT07312643Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule

Phase 1

Rec 0/0438 1 mg or Rec 0/0438 2 mg

Neurogenic Detrusor Overactivity

PHASE_1_2

Clinical Trials (1)

NCT03482037Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury

Phase 1/2

Pasireotide Long Acting Release

Neuroendocrine Tumors

PHASE_2

Udonitrectag

Neurotrophic Keratitis

PHASE_2

Dinutuximab Beta, Zoledronic acid, Interleukin-2

Leiomyosarcoma

PHASE_2

Clinical Trials (1)

NCT05080790Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma

Phase 2

Placebo

Essential Hypertension

PHASE_2

Clinical Trials (1)

NCT01093807Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension

Phase 2

Hemin

Gastroparesis

PHASE_2

Clinical Trials (1)

NCT01206582A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)

Phase 2

LCI699

Cushing Syndrome

PHASE_2

Clinical Trials (1)

NCT03708900Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

Phase 2

Siltuximab

Idiopathic Multicentric Castleman's Disease

PHASE_2

Clinical Trials (2)

NCT04975555Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Phase 2

NCT04838860Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease

Siltuximab

Schwannomatosis

PHASE_2

Clinical Trials (1)

NCT05684692Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

Phase 2

Osilodrostat 1 MG

Mild Autonomous Cortisol Secretion

PHASE_2

Clinical Trials (1)

NCT07104812Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

Phase 2

Siltuximab

Multiple Myeloma

PHASE_2

Clinical Trials (1)

NCT06679829A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Phase 2

Pasireotide Diaspartate

Post-Bariatric Hypoglycemia

PHASE_2

Clinical Trials (1)

NCT05928390Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

Phase 2

osilodrostat

Cushing's Syndrome

PHASE_2

Clinical Trials (1)

NCT03606408Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

Phase 2

Pasireotide

Prolactin-Producing Pituitary Tumor

PHASE_2

Clinical Trials (1)

NCT06295952A Study of Pasireotide in People With Prolactinoma

Phase 2

Methadone

Pain Related to Cancer

PHASE_3

Clinical Trials (1)

NCT01793480Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids.

Phase 3

Silodosin

Benign Prostatic Hyperplasia

PHASE_3

Clinical Trials (1)

NCT00359905Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH

Phase 3

Siltuximab

Acute Respiratory Distress Syndrome

PHASE_3

Mercaptamine

Cystinosis